Lesson plan

MDFEM

MDFEM, also known as 4-(2,2-difluoroethoxy)-2,5-dimethoxyamphetamine, is a serotonin receptor modulator of the phenethylamine, amphetamine, and DOx families. It is a derivative of the DOx psychedelics TMA-2 and MEM in which the 4-position substituent has been extended. The properties and effects of MDFEM in humans appear to be unknown. The drug is a partial agonist of the serotonin 5-HT 2A and 5-HT 2B receptors and also shows other receptor interactions. MDFEM was first described in the scientific literature by Daniel Trachsel by 2012.

Back to article

Article summary

MDFEM, also known as 4-(2,2-difluoroethoxy)-2,5-dimethoxyamphetamine, is a serotonin receptor modulator of the phenethylamine, amphetamine, and DOx families. It is a derivative of the DOx psychedelics TMA-2 and MEM in which the 4-position substituent has been extended. The properties and effects of MDFEM in humans appear to be unknown. The drug is a partial agonist of the serotonin 5-HT 2A and 5-HT 2B receptors and also shows other receptor interactions. MDFEM was first described in the scientific literature by Daniel Trachsel by 2012.

Key claims

No claims recorded.

Discussion questions

  1. Summarise the article in your own words. Which single claim would you verify first, and why?
  2. Which claim in this article is most likely to be revised as the sources update? How would you check its current status?
  3. If two sources disagreed about one of these facts, what would you need in order to trust one over the other?

Bibliography

No sources recorded.

Key claims and bibliography are generated from the same tracked claims and sources as the article page.